Weight Loss Industry Poised for Revolution With GLP-1 Pills


  • Flu Cases Surge Across US With Northeast at ‘Very High’ Activity

    03:01

  • Now Playing

    Weight Loss Drug Giants Prepare to Debut Oral GLP-1 Options

    03:29

  • UP NEXT

    Health Insurance Premiums to Skyrocket for Millions of Americans

    02:03

  • Officials Warn of Flu Case Surge in the Thick of Holiday Season

    02:12

  • Flu Cases Spike Across the US With Record Numbers

    00:18

  • Try These Tips for Staying Healthy During the Holiday Season

    04:28

  • Barry Manilow Reveals Lung Cancer Diagnosis, Postpones Shows

    02:51

  • FDA Approves Pill Version of Wegovy: What You Need to Know

    03:23

  • Flu Cases Surge Nationwide as Families Gather for Holidays

    02:23

  • Feeling Overwhelmed by the Holidays? How to Manage Stress

    05:43

  • How to Protect Yourself as Flu and Whooping Cough Cases Surge

    03:56

  • James Van Der Beek Opens Up to TODAY About Cancer Battle

    06:42

  • House Passes GOP Healthcare Bill Without Subsidy Extension

    02:17

  • Flu Case Numbers Spike Across US as the Holidays Approach

    04:13

  • How to Protect Yourself as Cold and Flu Season Ramps Up

    03:44

  • FDA Sends Warning to Retailers Selling Recalled Baby Formula

    00:33

  • How to Reframe the Way We Talk and Think About Menopause

    05:17

  • Can Lawmakers Find a Solution to Expiring Health Care Subsidies?

    05:04

  • Is the K-Beauty Trend Really Worth All the Hype?

    04:37

  • New Eli Lilly Weight Loss Drug Burns Fat, Reduces Knee Pain

    01:12

With Americans focused on getting fit in the new year, a groundbreaking new option is set to shift the weight loss landscape with two pharmaceutical giants both preparing to debut their oral GLP-1 options. The FDA approved Novo Nordisk’s once-daily Wegovy pill last week and Eli Lilly is awaiting FDA approval on its pill that saw adults lost 27 pounds over 72 weeks. NBC’s Maggie Vespa reports for TODAY.


Leave a Reply

Your email address will not be published. Required fields are marked *